Gabel D
Department of Chemistry, University of Bremen, Germany.
Strahlenther Onkol. 1993 Jan;169(1):65-70.
An analysis is carried out to evaluate the suitability of compounds for boron neutron capture therapy (BNCT). Suitable boron compounds are not necessarily those that show a high uptake ratio between tumor and healthy tissue. Compounds with lower uptake ratios, but higher concentrations in both healthy tissue and tumor, can be as effective in increasing the dose to the tumor over that of healthy tissue. In compound synthesis and evaluation, the parameters for optimization should therefore not be limited to the uptake ratio. A final assessment of the question whether and how well a given compound is suitable for BNCT can only be made after a study of its radiobiological effects on tissue. The analysis also illustrates the importance of beam quality in thermal and epithermal BNCT. An increase of adventitious radiation must be compensated by higher absolute tissue levels of a given boron compound and/or a higher uptake ratio, in order to arrive at the same dose differential between tumor and healthy tissue.
开展了一项分析以评估化合物对硼中子俘获疗法（BNCT）的适用性。合适的硼化合物不一定是那些在肿瘤组织与健康组织之间显示出高摄取率的化合物。摄取率较低但在健康组织和肿瘤组织中浓度较高的化合物，在增加肿瘤组织相对于健康组织的剂量方面可能同样有效。因此，在化合物合成和评估中，优化参数不应仅限于摄取率。只有在研究了给定化合物对组织的放射生物学效应之后，才能对该化合物是否适合以及在多大程度上适合BNCT进行最终评估。该分析还说明了热中子和超热中子BNCT中束流质量的重要性。为了在肿瘤组织和健康组织之间达到相同的剂量差异，必须通过给定硼化合物的更高绝对组织水平和/或更高摄取率来补偿偶然辐射的增加。
